ZURA BIO LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.19 USD | +0.58% |
|
+12.83% | +11.13% |
| May. 10 | Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating | MT |
| May. 09 | Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 203.6 | 374 | - | - |
| Enterprise Value (EV) 1 | 203.6 | 374 | 374 | 374 |
| P/E ratio | -2.23 x | -11.6 x | -7.32 x | -5.96 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -9.12 x | -7.79 x | -4.67 x |
| FCF Yield | - | -11% | -12.8% | -21.4% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 43,594 | 62,326 | - | - |
| Reference price 2 | 4.670 | 6.000 | 6.000 | 6.000 |
| Announcement Date | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -62.64 | -39.62 | -62.25 | -84.26 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -60.56 | -36.69 | -59.24 | -81.05 |
| Net income 1 | -60.36 | -36.69 | -59.24 | -81.05 |
| Net margin | - | - | - | - |
| EPS 2 | -2.090 | -0.5175 | -0.8200 | -1.006 |
| Free Cash Flow 1 | - | -41 | -48 | -80 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -33.9 | -10.19 | -10.83 | -8.379 | -8.953 | -10.1 | -12.34 | -12.96 | -14.19 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -34.02 | -8.27 | -8.473 | -7.747 | -8.337 | -9.178 | -11.44 | -11.85 | -13.04 |
| Net income 1 | -9.592 | -44.9 | -8.27 | -8.473 | -7.747 | -8.337 | -9.178 | -11.44 | -11.85 | -13.04 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -1.310 | -0.1800 | - | -0.0200 | -0.1400 | -0.1450 | -0.1675 | -0.1667 | -0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/12/23 | 8/14/23 | 11/13/23 | 3/28/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -41 | -48 | -80 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 2.54 | 2.55 | 2.55 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6
USD
Average target price
17.8
USD
Spread / Average Target
+196.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.13% | 374M | |
| +9.39% | 114B | |
| +11.50% | 104B | |
| -13.97% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.44% | 17.89B | |
| +6.79% | 14.28B | |
| +35.29% | 12.55B |
- Stock Market
- Equities
- ZURA Stock
- Financials Zura Bio Limited
